Table 1 Patient characteristics according to ISS.
Characteristics | N (%) | ISS | P-value | ||
|---|---|---|---|---|---|
I (n = 90) | II(n = 98) | III(n = 27) | |||
Gender | 0.688 | ||||
Female | 141(65.6%) | 62(68.9%) | 62(63.3%) | 17(63.0%) | |
Male | 74(34.4%) | 28(31.1%) | 36(36.7%) | 10(37.0%) | |
Age(years) | 0.609 | ||||
<60 y | 175(81.4%) | 76(84.4%) | 78(79.6%) | 21(77.8%) | |
≥60 y | 40(18.6%) | 14(15.6%) | 20(20.4%) | 6(22.2%) | |
Systemic symptoms | 0.011 | ||||
A | 143(66.5%) | 70(77.8%) | 56(57.1%) | 17(63.0%) | |
B | 72(33.5%) | 20(22.2%) | 42(42.9%) | 10(37.0%) | |
IPI score | 0.001 | ||||
0–2 | 157(73.0%) | 70(77.8%) | 73(74.5%) | 14(51.9%) | |
3–5 | 58(27.0%) | 20(22.2%) | 25(25.5%) | 13(48.1%) | |
Performance status | 0.239 | ||||
0–1 | 152(70.7%) | 66(73.3%) | 71(72.4%) | 15(55.6%) | |
2–4 | 63(29.3%) | 24(26.7%) | 25(27.6%) | 11(44.4%) | |
Lactate dehydrogenase | 0.019 | ||||
Normal | 101(47.0%) | 50(55.6%) | 44(44.9%) | 7(25.9%) | |
High | 114(53.0%) | 40(44.4%) | 54(55.1%) | 20(74.1%) | |
Ann Arbor stage | 0.082 | ||||
I or II | 89(41.4%) | 44(48.9%) | 38(38.8%) | 7(25.9%) | |
III or IV | 126(58.6%) | 46(51.1%) | 60(31.2%) | 20(74.1%) | |
No. of extranodal sites | 0.112 | ||||
0–1 | 113(52.6%) | 54(60.0%) | 44(44.9%) | 15(55.6%) | |
≥2 | 102(47.4%) | 36(40.0%) | 54(55.1%) | 12(44.4%) | |
Cell-of-origin subtype | 0.819 | ||||
GCB | 48(22.3%) | 23(33.3%) | 20(33.9%) | 5(26.3%) | |
NON-GCB | 99(46.0%) | 46(66.7%) | 39(66.1%) | 14(73.7%) | |
Treatment | |||||
CHOP | 78(36.3%) | 30(33.3%) | 43(43.9%) | 5(18.5%) | 0.899 |
R-CHOP | 137(63.7%) | 60(66.7%) | 55(56.1%) | 22(81.2%) | |
